Giving women POWER over AIDS
It’s a fact of life—and death. Biology and culture combine to put women at greater risk of contracting HIV than men, especially in developing countries. Marriage is no protection; in fact, it can increase a woman’s risk. Treatment has been revolutionary but treatment alone is no solution: in countries most affected by HIV disease, health systems are too overwhelmed by the epidemic to care for all who need it.

Prevention is part of the global strategy to combat HIV and AIDS, but existing HIV prevention strategies aren’t enough. We urgently need new prevention options, especially those that empower women to protect their own health and well-being. This is where microbicides can play a vital role. The International Partnership for Microbicides (IPM) is working to speed their development, specifically for use in developing countries, where women are at greatest risk for infection.

IPM is a non-profit organization committed to developing safe and effective microbicides and making them available worldwide. A successful microbicide would give women the power to protect themselves from HIV infection.
Vaginal microbicides are products being developed to prevent HIV transmission during sex. Because they are initiated by women, microbicides could offer women a powerful new method to prevent infection.

Developing a microbicide is a complex process that requires extensive research and collaboration with scientists, policymakers and advocates across the globe, as well as participation by thousands of clinical trial volunteers in communities where HIV and AIDS are most prevalent.

IPM is accelerating microbicide development by bringing together private sector technologies and public sector resources. IPM has engaged major pharmaceutical companies in the global microbicide effort, and partners with them to identify the most promising antiretroviral compounds. The microbicides being developed by IPM are based on antiretroviral medicines—the very drugs proven successful at treating HIV infection.

IPM already is working to ensure that once an effective microbicide is developed, it will be available to all women—to women in the world’s poorest countries first—as quickly as possible.
Created in 2002, IPM works by collaborating with a global network of partner organizations. It coordinates, helps fund, and directly conducts the different phases of work needed to bring microbicides from initial laboratory testing to final regulatory approval and product distribution.

Cover: Domithile Nyiraminani, photographed at a town hall in Kigali, Rwanda (Geoff Oliver Bugbee)

Left: Staff at IPM’s Clinical Trial Material facility in Bethlehem, Pa., sealing vaginal gel applicators for shipment to trial sites (Andrew Loxley, Felt Photography)

Inside Right: Nosiphiwo Zenani and her baby at a clinic in Masiphumelele, South Africa (Geoff Oliver Bugbee)
Partners
IPM collaborates with more than 75 organizations worldwide to expedite microbicide development, including universities, research institutions, nongovernmental organizations, advocacy groups and major corporations, as well as public health agencies and the national governments of countries hosting clinical studies.

Donors
Progress is fueled by financial support from nations across Europe and North America, the European Commission, the Bill & Melinda Gates Foundation, the Rockefeller Foundation, the United Nations Population Fund, and the World Bank.

Research & Development

Screening
IPM uses the latest scientific techniques to identify compounds that warrant further research and development.

Licensing agreements
Royalty-free licensing agreements with pharmaceutical companies allow IPM to develop promising compounds. If the compounds prove successful, these agreements give IPM full rights to distribute the product in resource-poor countries.

Market research
Because a microbicide will work only if women use it, IPM is conducting surveys in developing countries to learn which types of microbicide products women prefer.

Delivery mechanisms
Innovative forms of microbicides, such as long-acting vaginal gels, sustained-release intravaginal rings, and vaginal tablets and films, are being developed to give women more options.
Clinical Testing

Safety testing
Researchers test the safety of every microbicide candidate to the greatest extent possible before products are evaluated in large-scale studies that will determine product effectiveness.

Efficacy studies
To conduct these large-scale studies, IPM first studies HIV incidence in various countries to identify areas most suitable for efficacy trials. IPM then develops and strengthens new research centres, trains local staff, improves clinical infrastructure, and engages broader communities hosting the studies.

Access to Products

Selection
IPM prioritizes microbicide candidates based on scientific viability, acceptability among women who will use the products, cost, ease of manufacturing, and other factors that might affect access in developing countries.

Infrastructure
New infrastructures may be put in place within existing health systems to ensure that licensed microbicide products can be distributed with as little delay as possible.

Pre-launch planning
Research in health policy and the social sciences informs decisions that will shape product characteristics, financing, manufacturing and marketing strategies.
Together, we can make microbicides a reality

When will women in regions greatly affected by poverty and AIDS be able to protect themselves from HIV? There is no easy answer, but by working together we can speed the day when safe, effective, affordable microbicides are available to help millions of women live without HIV.

IPM donors include:

Bill & Melinda Gates Foundation
Belgian Development Cooperation
Canadian International Development Agency
Denmark Ministry of Foreign Affairs
European Commission
France Ministry of Foreign Affairs
Germany Federal Ministry for Economic Cooperation and Development
Irish Aid, Department of Foreign Affairs
Netherlands Ministry of Foreign Affairs
Norwegian Royal Ministry of Foreign Affairs
Rockefeller Foundation
Spain Ministry of Foreign Affairs and Cooperation
Sweden Ministry for Foreign Affairs
Swedish Department for Research Cooperation
United Kingdom Department for International Development
United Nations Population Fund
United States Agency for International Development
World Bank

This list includes all donors who have contributed to IPM since its founding in 2002 through 2008.
OUR MISSION: To prevent HIV transmission by accelerating the development and availability of safe and effective microbicides for use by women in developing countries.

IPM Headquarters
8401 Colesville Road, Suite 200
Silver Spring, MD 20910
United States
Tel: +1-301-608-2221
Fax: +1-301-608-2241

IPM Belgium
Rue du Trône, 98, 3rd floor
1050 Brussels,
Belgium
Tel: +32(0)2 507 1234
Fax: +32(0)2 507 1222

IPM South Africa
Main Street 121
Paarl 7646
South Africa
Tel: +27-21-860-2300
Fax: +27-21-860-2308
Mailing address:
PO Box 3460, Paarl, 7620 South Africa

Clinical Trial Material Facility
3894 Courtney Street, Suite 170
Bethlehem, PA 18017
United States
Tel: +1-484-893-1050
Fax: +1-484-893-1057

IPM’s 14,475-square-foot CTM facility produces, packages and ships gels and other delivery methods, such as vaginal rings, for use in clinical trials. The CTM is available as a resource for the broader microbicide field.

IPM has a dedicated staff of more than 160 in Belgium, South Africa and the United States.